N-Terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) as a Diagnostic Biomarker of Left Ventricular Systolic Dysfunction in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)

Andrijević, Ilija; Milutinov, Senka; Crvenković, Zagorka Lozanov; Matijašević, Jovan; Andrijevic, Ana; Kovačević, Tomi; Bokan, Darijo; Zarić, Bojan

doi:10.1007/s00408-018-0137-3

Cited by 13 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, HTN was found in 77.84% of patients. Close to our study Andrijevic et al (12) reported that 41.63% of patients were smokers.…”

Section: Discussionsupporting

confidence: 57%

See 1 more Smart Citation

Evaluation of The Diagnostic Value of Brain Natriuretic Peptide for Detection of Left Ventricular Systolic Dysfunction and Pulmonary Hypertension in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Azeem¹,

Zaghlol²,

Lotfi³

2022

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: One of the most critical health concerns of our day is acute deterioration of chronic obstructive lung disease (COPD). Detecting concurrent heart illness in these individuals might be challenging.Objective: Aims of this study were determining the diagnostic value of B-type natriuretic peptide (BNP) levels in the identification of acute COPD exacerbations (AECOPD) that were linked with left ventricular (LV) dysfunction and pulmonary hypertension. Methods: a prospective study of 100 patients with acute COPD exacerbations was done. All research participants were subjected to history taking, clinical examination, laboratory testing, blood gas analysis, echocardiography, and NT-pro BNP plasma level estimation. Results: Receiver operating characteristic (ROC) curve for BNP as a diagnostic for LV systolic dysfunction showed that area under the curve (AUC) was 0.923 at cut off point of 72.1 ng/ml with sensitivity of 93.3% and specificity of 84.6% (P<0.001). Conclusion:Heart failure is confirmed when the average natriuretic (NT)-BNP level in the left ventricle during AECOPD is higher than normal, which should prompt quick treatment for both conditions.

show abstract

“…However, HTN was found in 77.84% of patients. Close to our study Andrijevic et al (12) reported that 41.63% of patients were smokers.…”

Section: Discussionsupporting

confidence: 57%

“…Prosen and associates (17) , found 92% sensitivity, 89% specificity, 86% negative predictive value (NPV), and 90% positive predictive value (PPV) for diagnosis of heart failure in AECOPD. In the latest study by Andrijevic et al (12) sensitivity, specificity, PPV, and NPV were 76.6, 83.33, 57.14, and 92.47%. They were close to our results.…”

Section: Discussionmentioning

confidence: 89%

Evaluation of The Diagnostic Value of Brain Natriuretic Peptide for Detection of Left Ventricular Systolic Dysfunction and Pulmonary Hypertension in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Azeem¹,

Zaghlol²,

Lotfi³

2022

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

show abstract

“…Studies show that an elevated BNP level is associated with heart failure and that the detection of the BNP content is expected to be used for clinical heart failure screening [ 28 ]. Left ventricular systolic dysfunction (LVSD) and cardiac decompensation are usually accompanied by AECOPD, and studies have shown that NT-proBNP can be used as a diagnostic marker for LVSD in acute exacerbation of COPD [ 29 ]. The results of the present study showed that the serum BNP level in patients with COPD was significantly higher than that in the control group.…”

Section: Discussionmentioning

confidence: 99%

Association of brain natriuretic peptide gene polymorphisms with chronic obstructive pulmonary disease complicated with pulmonary hypertension and its mechanism

et al. 2018

View full text Add to dashboard Cite

Objective: To examine the association between brain natriuretic peptide (BNP) gene single nucleotide polymorphisms (SNPs) and chronic obstructive pulmonary disease (COPD) and COPD with pulmonary hypertension (PH) and to analyze its mechanism. Methods: The genotypes of BNP at the rs198389, rs6668352, and rs198388 loci in 339 patients with COPD (205 in the COPD/PH− group and 134 in the COPD/PH+ group) and 125 healthy subjects were detected by PCR/Sanger sequencing. The serum levels of BNP, fibrinogen (Fbg), and Apelin were measured in all subjects by ELISA. Results: The BNP rs198389 locus G allele, rs6668352 locus A allele, and 198388 locus T allele were high risk factors for COPD (P<0.001). Logistics regression analysis showed that BNP rs198389 locus G allele, rs6668352 locus A allele, and rs198388 locus T allele were high risk factors for PH in COPD patients (all P<0.001). The levels of the serum BNP and Fbg protein in the control group, COPD/PH− group, and COPD/PH+ group increased successively, and the expression levels of Apelin protein decreased successively (all P<0.001). The BNP and Fbg protein levels in the wild-type, heterozygote, and mutant homozygote in BNP rs198389, rs6668352, and rs198388 loci increased successively, and the serum Apelin protein levels decreased successively (all P<0.001). Conclusion: The polymorphisms of BNP at the rs198389, rs6668352, and rs198388 loci are associated with the occurrence of COPD and COPD with PH, and the occurrence may be related to the abnormal expression level of BNP, Fbg, and Apelin protein in the serum.

show abstract

“…As the prevalence of COPD increases, the prevalence of chronic pulmonary heart disease (CPHD) also increases. Current research results showed that COPD is the main cause of CPHD, accounting for about 87% of the prevalence of CPHD [ 3 ]. However, the current prevalence of COPD and CPHD in plateau areas and the influencing factors are still unclear, and further research is needed.…”

Section: Introductionmentioning

confidence: 99%

Analysis of Inducing Factors of Chronic Pulmonary Heart Disease Caused by Chronic Obstructive Pulmonary Disease at High Altitude through Epidemiological Investigation under Intelligent Medicine and Big Data

Huang¹,

Dang

2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

This study explores the risk factors of chronic pulmonary heart disease (CPHD) induced by plateau chronic obstructive pulmonary disease (COPD) based on intelligent medical treatment and big data of electrocardiogram (ECG) signal. Based on GPU, a wavelet algorithm is introduced to extract features of ECG signal, and it was combined with generalized regression neural network (GRNN) to improve classification accuracy. From June 2018 to December 2020, 10,185 patients diagnosed with COPD in the plateau area by pulmonary function testing, ECG, and chest X-ray at X Hospital are taken as the research objects to evaluate the distribution of CPHD incidence at different ages and altitudes. The running time of GTX780Ti is about 15 times shorter than that of CPU. The accuracy of N detection based on the GPU-accelerated neural network model reached 98.06%. Accuracy (Acc), sensitivity (Se), specificity (Sp), and positive rate (PR) of V were 99.03%, 89.17%, 98.92%, and 93.18%, respectively. The Acc, Se, Sp, and PR of S were 99.54%, 86.22%, 99.74%, and 92.56%, respectively. The GRNN classification accuracy was up to 98%. 19% of COPD patients were diagnosed with CPHD, including 1,409 males (72.82%) and 526 females (36.24%). The highest prevalence of CPHD was 64.60% when the altitude was 1,900–2,499 m, and the prevalence was only 2.43% when the altitude was ≥3,500 m. The highest prevalence of CPHD was 63.77% at the age of 61–70 years, and the lowest prevalence at the age of 15∼20 years was only 0.26%. Therefore, the GPU-based neural network model improved the classification accuracy of ECG signals. Age and altitude were risk factors for CPHD induced by high-altitude COPD, which provided a reference for the prevention, diagnosis, and treatment of CPHD in high-altitude areas.

show abstract

N-Terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) as a Diagnostic Biomarker of Left Ventricular Systolic Dysfunction in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)

Abstract: At the cut-off value of 1505 pg/mL NT-proBNP could be used as a diagnostic marker for LVSD in acute exacerbation of COPD.

Cited by 13 publications

References 22 publications

Evaluation of The Diagnostic Value of Brain Natriuretic Peptide for Detection of Left Ventricular Systolic Dysfunction and Pulmonary Hypertension in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Evaluation of The Diagnostic Value of Brain Natriuretic Peptide for Detection of Left Ventricular Systolic Dysfunction and Pulmonary Hypertension in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Association of brain natriuretic peptide gene polymorphisms with chronic obstructive pulmonary disease complicated with pulmonary hypertension and its mechanism

Analysis of Inducing Factors of Chronic Pulmonary Heart Disease Caused by Chronic Obstructive Pulmonary Disease at High Altitude through Epidemiological Investigation under Intelligent Medicine and Big Data

Contact Info

Product

Resources

About